Palvella Therapeutics
PVLA
43 hedge funds and large institutions have $12M invested in Palvella Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 12 closing their positions.
2,300% more call options, than puts
Call options by funds: $24K | Put options by funds: $1K
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
50% more capital invested
Capital invested by funds: $8.04M → $12M (+$3.98M)
0.23% less ownership
Funds ownership: 0.74% → 0.51% (-0.23%)
12% less funds holding
Funds holding: 49 → 43 (-6)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$102K |
| 2 |
Millennium Management
New York
|
+$60.6K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$26.7K |
| 4 |
Prudential Financial
Newark,
New Jersey
|
+$26.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$26.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$1.09M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$393K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$159K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$17.7K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BBA
51
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$1.35K | -131 | Closed |
|
|
OC
52
Oppenheimer & Co
New York
| – | -$1.74K | -131 | Closed |
|
53
Cerity Partners
New York
| – | -$1.71K | -129 | Closed |
|
|
NC
54
NewSquare Capital
Newtown Square,
Pennsylvania
| – | -$18 | -1 | Closed |
|
PVLA Hedge Fund Activity: Q3 2023 in Review
43 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2023, worth a combined $12M — up 50% from $8.04M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of PVLA and 6 opened new positions — a net loss of 6 holders — while 5 trimmed existing stakes and 11 added.
The largest buyer was Acadian Asset Management, adding an estimated $102K. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $1.09M sold.
- 43 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2023, down from 49 in Q2 2023.
- Funds reported $12M of Palvella Therapeutics stock for Q3 2023, up 50% quarter-over-quarter.
- 6 funds opened new Palvella Therapeutics positions in Q3 2023 and 12 closed out, a net change of -6 holders.
- The largest Palvella Therapeutics buyer in Q3 2023 was Acadian Asset Management, an estimated $102K added.
- The largest Palvella Therapeutics seller in Q3 2023 was Octagon Capital Advisors, an estimated $1.09M sold.
Based on aggregated 13F filings for Q3 2023.